Novartis’ Reclast Approved for Postmenopausal Osteoporosis

Drug Industry Daily
A A
The FDA has approved Novartis’ Reclast as the first once-yearly treatment for postmenopausal osteoporosis, the company announced Aug. 18.

To View This Article:

Login

Subscribe To Drug Industry Daily